No improvement in OS, but more grade 3 or higher AEs with atezolizumab plus SBRT among patients with inoperable early-stage NSCLC By Ogkologos - September 24, 2026 55 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SWOG/NRG S1914 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma Chemotherapy-Free Regimen of Targeted Agent and Immunotherapeutic Superior to Imatinib and Chemotherapy Among Adult Patients with Ph-positive ALL Meet the first recipient of the ESMO Artificial Intelligence Fellowship MOST POPULAR Medical Cannabis Formulation May Be Capable of Killing Breast Cancer Cells,... May 21, 2021 Firefighter Advocates For Men’s Health While He Battles Breast Cancer In... September 22, 2021 120 years of Cancer Research UK: how science transformed survival rates December 19, 2022 Navigating the Challenges of Gynecologic Cancer Survivorship: An Expert Perspective May 10, 2022 Load more HOT NEWS Should CAR T Cells Be Used Earlier in People with Non-Hodgkin... FDA Approves Tremelimumab in Combination with Durvalumab for Unresectable Hepatocellular Carcinoma EMA Recommends Granting a Marketing Authorisation for Generic Abiraterone for the... After Spine Tumor, Teacher Goes On Mission To Serenade Hospital Patients...
